SCHEMBL4674580

SCHEMBL4674580

O=C(O)C(O)=CC(=O)c1cnn(S(=O)(=O)c2ccc(Cl)cc2)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
AKR1C3 P42330 2/20 0.37
LMNA P02545 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
AKR1C2 P52895 1/20 0.37
AKR1C1 Q04828 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GRM4 Q14833 3/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CNR1 P21554 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MMP3 P08254 2/20 0.34
MMP8 P22894 2/20 0.34
EGLN1 Q9GZT9 1/20 0.34
CMA1 P23946 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4671799 0.88 GRM4 (0.37) ALDH1A1LMNASMN1; SMN2GRM4
SCHEMBL4670937 0.88 MAPT (0.38) AKR1C3LMNAMEN1KMT2AAKR1C2
SCHEMBL4672618 0.79 CXCR3 (0.35) ALDH1A1AKR1C3LMNAMEN1KMT2A
SCHEMBL4677715 0.79 GRM4 (0.33) ALDH1A1AKR1C3LMNAMEN1KMT2A
SCHEMBL4677989 0.77 ALDH1A1 (0.63) ALDH1A1AKR1C3MEN1KMT2AAKR1C2
SCHEMBL4677987 0.77 ALDH1A1 (0.63) ALDH1A1AKR1C3MEN1KMT2AAKR1C2
SCHEMBL4675007 0.76 AKR1C3 (0.44) ALDH1A1AKR1C3MEN1KMT2AAKR1C2
SCHEMBL7236361 0.75 TSHR (0.35) ALDH1A1AKR1C3LMNAMEN1KMT2A
SCHEMBL7236366 0.75 TSHR (0.35) ALDH1A1AKR1C3LMNAMEN1KMT2A
SCHEMBL4673009 0.73 ALDH1A1 (0.45) ALDH1A1AKR1C3LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885AKR1C3 30/4885LMNA 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.